Outcomes of weight-based heparin dosing based on literature guidelines and institution individualization

被引:3
|
作者
Davydov, L
Dietz, PA
Lewis, P
Twichell, ML
Bertino, JS [1 ]
机构
[1] Bassett Healthcare, Clin Pharm Serv, Clin Pharmacol Res Ctr, Cooperstown, NY 13326 USA
[2] Bassett Healthcare, Dept Surg, Cooperstown, NY 13326 USA
[3] Bassett Healthcare, Dept Nursing, Cooperstown, NY 13326 USA
[4] Bassett Healthcare, Dept Pharm Serv, Cooperstown, NY 13326 USA
[5] Bassett Healthcare, Dept Med, Cooperstown, NY 13326 USA
[6] St Johns Univ, Sch Pharm, Jamaica, NY 11439 USA
来源
PHARMACOTHERAPY | 2000年 / 20卷 / 10期
关键词
D O I
10.1592/phco.20.15.1179.34589
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study Objective. To determine whether unfractionated heparin is optimally dosed using published weight-based guidelines. Design. Six-month, prospective study. Setting. University hospital. Patients. Ninety-six patients in the weight-based unfractionated heparin-dosing group 1 (WBHD1; 37 men; mean age 66.9 +/- 15.1 years; mean weight 80.1 +/- 20.6 kg) and 68 patients in the WBHD2 (25 men; mean age 68.2 +/- 15.6 years; mean weight 82.0 +/- 19.6 kg). Interventions. The WBHD1 received a 100-U/kg intravenous bolus followed by an 18-U/kg/hour continuous intravenous infusion. After 3 months, the protocol was modified, and the WBHD2 received a 90-U/kg bolus followed by a 16-U/kg/hour continuous infusion for 3 months. Measurements and Main Results. Activated partial thromboplastin times (aPTTs), frequency of bleeding episodes that required blood transfusions, and the number of recurrent thromboembolic events were collected from both groups after 3 months on the study. In the WBHD1, 24 hours after starting heparin, 38.5% of patients had therapeutic aPTTs, and at 48 hours, 54.3% were therapeutic. In the WBHD2, 42.6% and 51.4% of patients had therapeutic aPTTs at 24 and 48 hours, respectively. There was no statistical difference between the WBHD1 and WBHD2 in the percentage of patients with therapeutic aPTTs. Conclusions. Weight-based heparin dosing resulted in low percentages of patients with therapeutic aPTTs. The use of weight alone to dose heparin may not be adequate to optimize therapy.
引用
收藏
页码:1179 / 1183
页数:5
相关论文
共 50 条
  • [1] Reevaluation of a weight-based heparin dosing nomogram: Is institution-specific modification necessary?
    Schlicht, JR
    Sunyecz, L
    Weber, RJ
    Tabas, GH
    Smith, RE
    ANNALS OF PHARMACOTHERAPY, 1997, 31 (12) : 1454 - 1459
  • [2] Optimal weight base for a weight-based heparin dosing protocol
    Yee, WP
    Norton, LL
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1998, 55 (02) : 159 - 162
  • [3] Evaluating a weight-based heparin dosing and monitoring practice
    Fetrow, CW
    McCoy, L
    FORMULARY, 1997, 32 (05) : 538 - &
  • [4] Are you up to date on weight-based heparin dosing?
    Sparks, KS
    AMERICAN JOURNAL OF NURSING, 1996, 96 (04) : 33 - 37
  • [5] Weight-based heparin dosing: Clinical response and resource utilization
    Lackie, CL
    Luzier, AB
    Donovan, JA
    Feras, HI
    Forrest, A
    CLINICAL THERAPEUTICS, 1998, 20 (04) : 699 - 710
  • [6] Evaluation of Weight-Based Dosing of Unfractionated Heparin in Obese Children
    Taylor, BreAnn N.
    Bork, Sara J. D.
    Kim, Shelly
    Moffett, Brady S.
    Yee, Donald L.
    JOURNAL OF PEDIATRICS, 2013, 163 (01): : 150 - 153
  • [7] EXPOSURE AND OUTCOMES ASSOCIATED WITH WEIGHT-BASED NOREPINEPHRINE DOSING
    Huang, Ellen
    Jun, Ah Hyun
    Azimi, Hanna
    Petway, Justin
    CRITICAL CARE MEDICINE, 2021, 49 (01) : 443 - 443
  • [8] Weight-based heparin dosing: Maybe it's just a matter of time
    Susla, GM
    CRITICAL CARE MEDICINE, 1997, 25 (09) : 1451 - 1452
  • [9] Development of a weight-based heparin dosing nomogram in trauma patients (TP)
    Regan, ME
    Vanderheyden, BA
    Buck, BD
    Wiles, CE
    CRITICAL CARE MEDICINE, 1999, 27 (01) : A179 - A179
  • [10] Comparison of a weight-based heparin nomogram with traditional heparin dosing to achieve therapeutic anticoagulation
    Shalansky, KF
    FitzGerald, JM
    Sunderji, R
    Traboulay, SJ
    OMalley, B
    McCarron, BI
    Naiman, S
    PHARMACOTHERAPY, 1996, 16 (06): : 1076 - 1084